Loading…
Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis
Purpose: Retinoic acid receptor-β 2 (RAR-β 2 ) expression is suppressed in oral premalignant lesions and head and neck squamous cell carcinomas (HNSCCs). This study was conducted to determine whether RAR-β 2 gene expression in such lesions can be silenced by promoter methylation. Experimental Design...
Saved in:
Published in: | Clinical cancer research 2004-03, Vol.10 (5), p.1733-1742 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 1742 |
container_issue | 5 |
container_start_page | 1733 |
container_title | Clinical cancer research |
container_volume | 10 |
creator | YOUSSEF, Emile M LOTAN, Dafna HONG, Waun K LOTAN, Reuben ISSA, Jean-Pierre WAKASA, Kenichi FAN, You-Hong LI MAO HASSAN, Khaled LEI FENG LEE, J. Jack LIPPMAN, Scott M |
description | Purpose: Retinoic acid receptor-β 2 (RAR-β 2 ) expression is suppressed in oral premalignant lesions and head and neck squamous cell carcinomas (HNSCCs). This study was
conducted to determine whether RAR-β 2 gene expression in such lesions can be silenced by promoter methylation.
Experimental Design: RAR-β 2 methylation was analyzed in DNA samples from 22 pairs of primary HNSCC and adjacent normal epithelium, 124 samples of oral
leukoplakia, and 18 HNSCC cell lines using methylation-specific PCR. RAR-β 2 promoter was methylated in 67, 56, and 53% of HNSCC tumors, HNSCC cell lines, and microdissected oral leukoplakia specimens,
respectively. RAR-β 2 hypermethylation was confirmed by sodium bisulfite-PCR combined with restriction enzyme digestion analysis and by random
cloning and sequencing of bisulfite-treated DNA isolates.
Results: Significantly higher RAR-β 2 hypermethylation levels were found in tumor tissue compared with adjacent normal tissue ( P = 0.002). RAR-β 2 methylation in the cell lines was correlated with loss of RAR-β 2 expression ( P = 0.013) and inversely related to the presence of mutated p53 ( P = 0.025). The demethylating agent 5-aza-2′-deoxycytidine (5-aza-CdR) restored RAR-β 2 inducibility by all- trans -retinoic acid (ATRA) in some of the cell lines, which posses a methylated RAR-β 2 promoter. In some cell lines, this effect was associated with increased growth inhibition after combined treatment with 5-aza-CdR
and ATRA.
Conclusions: RAR-β 2 silencing by methylation is an early event in head and neck carcinogenesis; 5-Aza-CdR can restore RAR-β 2 inducibility by ATRA in most cell lines, and the combination of 5-aza-CdR and ATRA is more effective in growth inhibition
than single agents. |
doi_str_mv | 10.1158/1078-0432.CCR-0989-3 |
format | article |
fullrecord | <record><control><sourceid>pascalfrancis_highw</sourceid><recordid>TN_cdi_pascalfrancis_primary_15558521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15558521</sourcerecordid><originalsourceid>FETCH-LOGICAL-h199t-63a7ff35daf06c6d7fc14f7b22b691ca41519e9dc10c39410a62b0e299f431833</originalsourceid><addsrcrecordid>eNo1kMFKAzEQhoMotlbfwEMugpdoJtnsbo5l0VYoCkXxuKTZSTfa7i7JgvS1fBCfyUD1NP8w3__zM4RcA78DUOU98KJkPJPirqrWjOtSM3lCpqBUwaTI1WnS_8iEXMT4wTlkwLNzMgGVJBf5lLwvDwOGPY7tYWdG33e0d3Rska5x9F3vLZ1b36TN4jD2gf18C7rADqnv6BJNQ03X0Ge0n7QywSbHNh2jj5fkzJldxKu_OSNvjw-v1ZKtXhZP1XzFWtB6ZLk0hXNSNcbx3OZN4SxkrtgIsck1WJOBAo26scCt1Km9ycWGo9DaZRJKKWfk5pg7mGjNzgXTWR_rIfi9CYc6fUOVSkDibo9c67ftlw9Y20RiCBgxFW9r4LWqoZBS_gKUfWSU</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis</title><source>Freely Accessible Science Journals - check A-Z of ejournals</source><creator>YOUSSEF, Emile M ; LOTAN, Dafna ; HONG, Waun K ; LOTAN, Reuben ; ISSA, Jean-Pierre ; WAKASA, Kenichi ; FAN, You-Hong ; LI MAO ; HASSAN, Khaled ; LEI FENG ; LEE, J. Jack ; LIPPMAN, Scott M</creator><creatorcontrib>YOUSSEF, Emile M ; LOTAN, Dafna ; HONG, Waun K ; LOTAN, Reuben ; ISSA, Jean-Pierre ; WAKASA, Kenichi ; FAN, You-Hong ; LI MAO ; HASSAN, Khaled ; LEI FENG ; LEE, J. Jack ; LIPPMAN, Scott M</creatorcontrib><description>Purpose: Retinoic acid receptor-β 2 (RAR-β 2 ) expression is suppressed in oral premalignant lesions and head and neck squamous cell carcinomas (HNSCCs). This study was
conducted to determine whether RAR-β 2 gene expression in such lesions can be silenced by promoter methylation.
Experimental Design: RAR-β 2 methylation was analyzed in DNA samples from 22 pairs of primary HNSCC and adjacent normal epithelium, 124 samples of oral
leukoplakia, and 18 HNSCC cell lines using methylation-specific PCR. RAR-β 2 promoter was methylated in 67, 56, and 53% of HNSCC tumors, HNSCC cell lines, and microdissected oral leukoplakia specimens,
respectively. RAR-β 2 hypermethylation was confirmed by sodium bisulfite-PCR combined with restriction enzyme digestion analysis and by random
cloning and sequencing of bisulfite-treated DNA isolates.
Results: Significantly higher RAR-β 2 hypermethylation levels were found in tumor tissue compared with adjacent normal tissue ( P = 0.002). RAR-β 2 methylation in the cell lines was correlated with loss of RAR-β 2 expression ( P = 0.013) and inversely related to the presence of mutated p53 ( P = 0.025). The demethylating agent 5-aza-2′-deoxycytidine (5-aza-CdR) restored RAR-β 2 inducibility by all- trans -retinoic acid (ATRA) in some of the cell lines, which posses a methylated RAR-β 2 promoter. In some cell lines, this effect was associated with increased growth inhibition after combined treatment with 5-aza-CdR
and ATRA.
Conclusions: RAR-β 2 silencing by methylation is an early event in head and neck carcinogenesis; 5-Aza-CdR can restore RAR-β 2 inducibility by ATRA in most cell lines, and the combination of 5-aza-CdR and ATRA is more effective in growth inhibition
than single agents.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-0989-3</identifier><identifier>PMID: 15014026</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Medical sciences ; Pharmacology. Drug treatments ; Tumors</subject><ispartof>Clinical cancer research, 2004-03, Vol.10 (5), p.1733-1742</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15558521$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>YOUSSEF, Emile M</creatorcontrib><creatorcontrib>LOTAN, Dafna</creatorcontrib><creatorcontrib>HONG, Waun K</creatorcontrib><creatorcontrib>LOTAN, Reuben</creatorcontrib><creatorcontrib>ISSA, Jean-Pierre</creatorcontrib><creatorcontrib>WAKASA, Kenichi</creatorcontrib><creatorcontrib>FAN, You-Hong</creatorcontrib><creatorcontrib>LI MAO</creatorcontrib><creatorcontrib>HASSAN, Khaled</creatorcontrib><creatorcontrib>LEI FENG</creatorcontrib><creatorcontrib>LEE, J. Jack</creatorcontrib><creatorcontrib>LIPPMAN, Scott M</creatorcontrib><title>Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis</title><title>Clinical cancer research</title><description>Purpose: Retinoic acid receptor-β 2 (RAR-β 2 ) expression is suppressed in oral premalignant lesions and head and neck squamous cell carcinomas (HNSCCs). This study was
conducted to determine whether RAR-β 2 gene expression in such lesions can be silenced by promoter methylation.
Experimental Design: RAR-β 2 methylation was analyzed in DNA samples from 22 pairs of primary HNSCC and adjacent normal epithelium, 124 samples of oral
leukoplakia, and 18 HNSCC cell lines using methylation-specific PCR. RAR-β 2 promoter was methylated in 67, 56, and 53% of HNSCC tumors, HNSCC cell lines, and microdissected oral leukoplakia specimens,
respectively. RAR-β 2 hypermethylation was confirmed by sodium bisulfite-PCR combined with restriction enzyme digestion analysis and by random
cloning and sequencing of bisulfite-treated DNA isolates.
Results: Significantly higher RAR-β 2 hypermethylation levels were found in tumor tissue compared with adjacent normal tissue ( P = 0.002). RAR-β 2 methylation in the cell lines was correlated with loss of RAR-β 2 expression ( P = 0.013) and inversely related to the presence of mutated p53 ( P = 0.025). The demethylating agent 5-aza-2′-deoxycytidine (5-aza-CdR) restored RAR-β 2 inducibility by all- trans -retinoic acid (ATRA) in some of the cell lines, which posses a methylated RAR-β 2 promoter. In some cell lines, this effect was associated with increased growth inhibition after combined treatment with 5-aza-CdR
and ATRA.
Conclusions: RAR-β 2 silencing by methylation is an early event in head and neck carcinogenesis; 5-Aza-CdR can restore RAR-β 2 inducibility by ATRA in most cell lines, and the combination of 5-aza-CdR and ATRA is more effective in growth inhibition
than single agents.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNo1kMFKAzEQhoMotlbfwEMugpdoJtnsbo5l0VYoCkXxuKTZSTfa7i7JgvS1fBCfyUD1NP8w3__zM4RcA78DUOU98KJkPJPirqrWjOtSM3lCpqBUwaTI1WnS_8iEXMT4wTlkwLNzMgGVJBf5lLwvDwOGPY7tYWdG33e0d3Rska5x9F3vLZ1b36TN4jD2gf18C7rADqnv6BJNQ03X0Ge0n7QywSbHNh2jj5fkzJldxKu_OSNvjw-v1ZKtXhZP1XzFWtB6ZLk0hXNSNcbx3OZN4SxkrtgIsck1WJOBAo26scCt1Km9ycWGo9DaZRJKKWfk5pg7mGjNzgXTWR_rIfi9CYc6fUOVSkDibo9c67ftlw9Y20RiCBgxFW9r4LWqoZBS_gKUfWSU</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>YOUSSEF, Emile M</creator><creator>LOTAN, Dafna</creator><creator>HONG, Waun K</creator><creator>LOTAN, Reuben</creator><creator>ISSA, Jean-Pierre</creator><creator>WAKASA, Kenichi</creator><creator>FAN, You-Hong</creator><creator>LI MAO</creator><creator>HASSAN, Khaled</creator><creator>LEI FENG</creator><creator>LEE, J. Jack</creator><creator>LIPPMAN, Scott M</creator><general>American Association for Cancer Research</general><scope>IQODW</scope></search><sort><creationdate>20040301</creationdate><title>Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis</title><author>YOUSSEF, Emile M ; LOTAN, Dafna ; HONG, Waun K ; LOTAN, Reuben ; ISSA, Jean-Pierre ; WAKASA, Kenichi ; FAN, You-Hong ; LI MAO ; HASSAN, Khaled ; LEI FENG ; LEE, J. Jack ; LIPPMAN, Scott M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h199t-63a7ff35daf06c6d7fc14f7b22b691ca41519e9dc10c39410a62b0e299f431833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YOUSSEF, Emile M</creatorcontrib><creatorcontrib>LOTAN, Dafna</creatorcontrib><creatorcontrib>HONG, Waun K</creatorcontrib><creatorcontrib>LOTAN, Reuben</creatorcontrib><creatorcontrib>ISSA, Jean-Pierre</creatorcontrib><creatorcontrib>WAKASA, Kenichi</creatorcontrib><creatorcontrib>FAN, You-Hong</creatorcontrib><creatorcontrib>LI MAO</creatorcontrib><creatorcontrib>HASSAN, Khaled</creatorcontrib><creatorcontrib>LEI FENG</creatorcontrib><creatorcontrib>LEE, J. Jack</creatorcontrib><creatorcontrib>LIPPMAN, Scott M</creatorcontrib><collection>Pascal-Francis</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YOUSSEF, Emile M</au><au>LOTAN, Dafna</au><au>HONG, Waun K</au><au>LOTAN, Reuben</au><au>ISSA, Jean-Pierre</au><au>WAKASA, Kenichi</au><au>FAN, You-Hong</au><au>LI MAO</au><au>HASSAN, Khaled</au><au>LEI FENG</au><au>LEE, J. Jack</au><au>LIPPMAN, Scott M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis</atitle><jtitle>Clinical cancer research</jtitle><date>2004-03-01</date><risdate>2004</risdate><volume>10</volume><issue>5</issue><spage>1733</spage><epage>1742</epage><pages>1733-1742</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Retinoic acid receptor-β 2 (RAR-β 2 ) expression is suppressed in oral premalignant lesions and head and neck squamous cell carcinomas (HNSCCs). This study was
conducted to determine whether RAR-β 2 gene expression in such lesions can be silenced by promoter methylation.
Experimental Design: RAR-β 2 methylation was analyzed in DNA samples from 22 pairs of primary HNSCC and adjacent normal epithelium, 124 samples of oral
leukoplakia, and 18 HNSCC cell lines using methylation-specific PCR. RAR-β 2 promoter was methylated in 67, 56, and 53% of HNSCC tumors, HNSCC cell lines, and microdissected oral leukoplakia specimens,
respectively. RAR-β 2 hypermethylation was confirmed by sodium bisulfite-PCR combined with restriction enzyme digestion analysis and by random
cloning and sequencing of bisulfite-treated DNA isolates.
Results: Significantly higher RAR-β 2 hypermethylation levels were found in tumor tissue compared with adjacent normal tissue ( P = 0.002). RAR-β 2 methylation in the cell lines was correlated with loss of RAR-β 2 expression ( P = 0.013) and inversely related to the presence of mutated p53 ( P = 0.025). The demethylating agent 5-aza-2′-deoxycytidine (5-aza-CdR) restored RAR-β 2 inducibility by all- trans -retinoic acid (ATRA) in some of the cell lines, which posses a methylated RAR-β 2 promoter. In some cell lines, this effect was associated with increased growth inhibition after combined treatment with 5-aza-CdR
and ATRA.
Conclusions: RAR-β 2 silencing by methylation is an early event in head and neck carcinogenesis; 5-Aza-CdR can restore RAR-β 2 inducibility by ATRA in most cell lines, and the combination of 5-aza-CdR and ATRA is more effective in growth inhibition
than single agents.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>15014026</pmid><doi>10.1158/1078-0432.CCR-0989-3</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1078-0432 |
ispartof | Clinical cancer research, 2004-03, Vol.10 (5), p.1733-1742 |
issn | 1078-0432 1557-3265 |
language | eng |
recordid | cdi_pascalfrancis_primary_15558521 |
source | Freely Accessible Science Journals - check A-Z of ejournals |
subjects | Antineoplastic agents Biological and medical sciences Medical sciences Pharmacology. Drug treatments Tumors |
title | Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A19%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypermethylation%20of%20the%20Retinoic%20Acid%20Receptor-%CE%B22%20Gene%20in%20Head%20and%20Neck%20Carcinogenesis&rft.jtitle=Clinical%20cancer%20research&rft.au=YOUSSEF,%20Emile%20M&rft.date=2004-03-01&rft.volume=10&rft.issue=5&rft.spage=1733&rft.epage=1742&rft.pages=1733-1742&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-0989-3&rft_dat=%3Cpascalfrancis_highw%3E15558521%3C/pascalfrancis_highw%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h199t-63a7ff35daf06c6d7fc14f7b22b691ca41519e9dc10c39410a62b0e299f431833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/15014026&rfr_iscdi=true |